Dr Morris is a Research Fellow with the Heart, Trauma & Sepsis Research Laboratory. She has over 20 years experience with in vitro and in vivo models of disease, characterisation of the immunopathogenesis of disease, and preclinical evaluation of novel therapies. 



  • 2017 to 2019 - Senior Research Fellow, Orthopaedic Research Institute of Queensland (Townsville)
  • 2008 to 2016 - Senior Research Associate, James Cook University (Townsville)
Research Disciplines
Socio-Economic Objectives

These are the most recent publications associated with this author. To see a detailed profile of all publications stored at JCU, visit ResearchOnline@JCU. Hover over Altmetrics badges to see social impact.

Journal Articles

ResearchOnline@JCU stores 68+ research outputs authored by Dr Jodie Morris from 2001 onwards.

Current Funding

Current and recent Research Funding to JCU is shown by funding source and project.

United States Department of Defence - Traumatic Brain Injury and Psychological Health, Investigator Initiated Research Award

Point-of-injury intranasal ALM drug therapy to reduce secondary injury and improve outcomes after TBI in civilian and military resource-limited environments

Indicative Funding
$932,919 over 3 years
Currently there is no effective drug therapy to treat traumatic brain injury (TBI) in combat and other military and civilian settings immediately after the injury has occurred that can protect the brain and the whole body by reducing secondary injury progression and TBI-associated complications. ALM therapy is a neuroprotective fluid therapy that significantly improves survival, rescues cardiac function, reduces local bleeding, and blunts secondary injury processes including inflammation after trauma. This project will evaluate the efficacy and protective benefits of ALM therapy administered intravenously (injectable) and intranasally (via spray) in a rat model of TBI.
Geoffrey Dobson, Hayley Letson and Jodie Morris (College of Medicine & Dentistry)
Traumatic Brain Injury; intranasal; Blood brain barrier; Military; Immune; ALM

United States Department of Defence - DoD Peer Reviewed Orthopaedic Research Program (PRORP) - Applied Research Award

ALM Drug Therapy to reduce inflammation and scar formation after ACL reconstruction surgery: Targeting earlier return to active duty.

Indicative Funding
$1,061,864 over 4 years
Two complications of anterior cruciate ligament (ACL) reconstruction surgery are cartilage degeneration and scarring within the joint, which can prolong healing, promote pain and restrict knee movement. Our project will evaluate a new therapy known as ALM solution that can be administrered during ACL reconstruction surgery to dampen inflammation, protect cartilage and promote tissue healing within the joint. Our study has the potential to expedite a patient's return to an active duty with fewer complications.
Geoffrey Dobson, Peter McEwen, Jodie Morris, Hayley Letson and Erik Biros (College of Medicine & Dentistry)
ACL Injury; ACL Reconstruction surgery; Scarring; Osteoarthritis; Inflammation; Therapeutics

These are the most recent metadata records associated with this researcher. To see a detailed description of all dataset records, visit Research Data Australia.

Connect with me
Share my profile
Share my profile:

  • 47.113A, Pharmacy and Medical Research (Townsville campus)
Advisory Accreditation
Primary Advisor
Find me on…
Icon for Scopus Author page Icon for Google Scholar profile Icon for ResearchGate profile

Similar to me

  1. Dr Erik Biros
  2. Dr Hayley Letson
  3. Dr Paul Giacomin
    Australian Institute of Tropical Health & Medicine
  4. Dr Roland Ruscher
    Australian Institute of Tropical Health & Medicine